Entera Bio: A Look into the Treatment Landscape for Osteoporosis and Entera Bio’s Potential Impact
|DATE:||September 28, 2022|
|TIME:||10:00 AM EDT|
About The Event
Join us for an Entera Bio KOL Webinar, featuring presentations from Key Opinion Leaders (KOLs) John P. Bilezikian, MD, PhD (Columbia University), Felicia Cosman, MD (Columbia University), and Bart L. Clarke, MD (Mayo Clinic).
The event will provide insight into the current treatment landscape and unmet medical need for post-menopausal women with osteoporosis. The discussion will focus on Entera Bio’s development of EB613, a proprietary formulation of PTH (1-34, teriparatide) as the first potential orally administered osteoanabolic treatment. Entera leadership will review their Phase 2 EB613 data, which will be followed by an overview of the Company’s proposed registrational Phase 3 plan submitted to FDA.
A live Q&A session will follow the presentations.